Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04681248
Expanded Access Status : Available
First Posted : December 23, 2020
Last Update Posted : December 23, 2020
Sponsor:
Information provided by (Responsible Party):
Leap Therapeutics, Inc.

Tracking Information
First Submitted Date December 18, 2020
First Posted Date December 23, 2020
Last Update Posted Date December 23, 2020
 
Descriptive Information
Brief Title Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Brief Summary An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.
Detailed Description This is a intermediate-size Expanded Access Protocol (EAP). Patients who were receiving DKN-01 in a parent study at the time of completion of the parent study, and are, in the opinion of the Investigator and Sponsor, suitable candidates for continued study drug treatment are eligible for participation in the current EAP. In this EAP, all patients will receive DKN-01 at the same dose and schedule as at the time of completion of the parent study. Furthermore, patients who received DKN-01 in combination in the parent study will continue to receive the same combination agent at the same dose and schedule in the EAP.
Study Type Expanded Access
Expanded Access Type Intermediate-size Population
Intervention Drug: DKN-01
Administered by IV infusion
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status Available
Contacts
Contact: Cyndi Sirard, MD 617-714-0357 csirard@leaptx.com
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04681248
Responsible Party Leap Therapeutics, Inc.
Study Sponsor Leap Therapeutics, Inc.
Collaborators Not Provided
Investigators
Study Director: Cyndi Sirard, MD Leap Therapeutics
PRS Account Leap Therapeutics, Inc.
Verification Date December 2020